Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective
The addition of baricitinib to formularies is likely to increase the cost impact from a government hospital perspective. However, this addition expands the treatment options for patients with AA and may result in improved outcomes. Future cost-effectiveness analyses are recommended to estimate the cost per incremental improvement in the outcomes.
Authors
- Sinaa Al-Aqeel (ORCID: https://orcid.org/0000-0003-0571-7230)
- Mohammad F. Zaitoun (ORCID: https://orcid.org/0000-0002-1156-9281)
- S.T. Alhawwashi
- Saad Al-Qahtani (ORCID: https://orcid.org/0000-0002-5760-4433)
- Abdullah Al-Shahrani (ORCID: https://orcid.org/0000-0001-9280-5989)
- Mohammad Y. Alshahrani (ORCID: https://orcid.org/0000-0002-7096-0221)
- M.S. Al-Nasser
Institutions
- King Saud University (SA)
- Armed Forces Hospital (SA)
- Security Forces Hospital (SA)
- Armed Forces Hospital Southern Region
Publication Details
- Journal
- Saudi Pharmaceutical Journal
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1016/j.jsps.2024.102204
- Citations
- 1
- Primary Topic
- Biomedical Ethics and Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.33